remove inappropriate hatnote-style text
|
→Binding profiles: + wikilink Methylphenidate#Pharmacodynamics
|
||
(7 intermediate revisions by 6 users not shown) | |||
Line 1: | Line 1: | ||
{{Short description|Drug class}} |
|||
A '''monoamine reuptake inhibitor''' ('''MRI''')<ref name="pmid20200509">{{cite journal |vauthors=Axel AM, Mikkelsen JD, Hansen HH | title = Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat | journal = Neuropsychopharmacology | volume = 35 | issue = 7 | pages = 1464–76 |date=June 2010 | pmid = 20200509 | pmc = 3055463 | doi = 10.1038/npp.2010.16 }}</ref> is a [[drug]] that acts as a [[reuptake inhibitor]] of one or more of the three major [[monoamine neurotransmitter]]s [[serotonin]], [[norepinephrine]], and [[dopamine]] by blocking the action of one or more of the respective [[monoamine transporter]]s (MATs), which include the [[serotonin transporter]] (SERT), [[norepinephrine transporter]] (NET), and [[dopamine transporter]] (DAT). This in turn results in an increase in the [[synapse|synaptic]] [[concentration]]s of one or more of these neurotransmitters and therefore an increase in [[monoaminergic]] [[neurotransmission]]. |
A '''monoamine reuptake inhibitor''' ('''MRI''')<ref name="pmid20200509">{{cite journal |vauthors=Axel AM, Mikkelsen JD, Hansen HH | title = Tesofensine, a novel triple monoamine reuptake inhibitor, induces appetite suppression by indirect stimulation of alpha1 adrenoceptor and dopamine D1 receptor pathways in the diet-induced obese rat | journal = Neuropsychopharmacology | volume = 35 | issue = 7 | pages = 1464–76 |date=June 2010 | pmid = 20200509 | pmc = 3055463 | doi = 10.1038/npp.2010.16 }}</ref> is a [[drug]] that acts as a [[reuptake inhibitor]] of one or more of the three major [[monoamine neurotransmitter]]s [[serotonin]], [[norepinephrine]], and [[dopamine]] by blocking the action of one or more of the respective [[monoamine transporter]]s (MATs), which include the [[serotonin transporter]] (SERT), [[norepinephrine transporter]] (NET), and [[dopamine transporter]] (DAT). This in turn results in an increase in the [[synapse|synaptic]] [[concentration]]s of one or more of these neurotransmitters and therefore an increase in [[monoaminergic]] [[neurotransmission]]. |
||
==Uses== |
==Uses== |
||
The majority of currently approved [[antidepressant]]s act predominantly or exclusively as MRIs, including the [[selective serotonin reuptake inhibitor]]s (SSRIs), [[serotonin–norepinephrine reuptake inhibitor]]s (SNRIs), and almost all of the [[tricyclic antidepressant]]s (TCAs).<ref name="FinkelClark2008">{{cite book | author1 = Richard Finkel | author2 = Michelle Alexia Clark | author3 = Pamela C. Champe |author4=Luigi X. Cubeddu | title = Lippincott's Illustrated Reviews: Pharmacology | url = https://books.google.com/books?id=Q4hG2gRhy7oC&pg=PA141 | access-date = 12 May 2012 | date = 16 July 2008 | publisher = Lippincott Williams & Wilkins | isbn = 978-0-7817-7155-9 | page = 141}}</ref> Many [[psychostimulant]]s used either in the treatment of {{abbrlink|ADHD|attention-deficit hyperactivity disorder}} or as [[appetite suppressant]]s in the treatment of [[obesity]] also behave as MRIs, although notably amphetamine (and methamphetamine), which do act to some extent as monoamine reuptake inhibitors, exerts their effects primarily as releasing agents.<ref>{{Cite journal| |
The majority of currently approved [[antidepressant]]s act predominantly or exclusively as MRIs, including the [[selective serotonin reuptake inhibitor]]s (SSRIs), [[serotonin–norepinephrine reuptake inhibitor]]s (SNRIs), and almost all of the [[tricyclic antidepressant]]s (TCAs).<ref name="FinkelClark2008">{{cite book | author1 = Richard Finkel | author2 = Michelle Alexia Clark | author3 = Pamela C. Champe |author4=Luigi X. Cubeddu | title = Lippincott's Illustrated Reviews: Pharmacology | url = https://books.google.com/books?id=Q4hG2gRhy7oC&pg=PA141 | access-date = 12 May 2012 | date = 16 July 2008 | publisher = Lippincott Williams & Wilkins | isbn = 978-0-7817-7155-9 | page = 141}}</ref> Many [[psychostimulant]]s used either in the treatment of {{abbrlink|ADHD|attention-deficit hyperactivity disorder}} or as [[appetite suppressant]]s in the treatment of [[obesity]] also behave as MRIs, although notably amphetamine (and methamphetamine), which do act to some extent as monoamine reuptake inhibitors, exerts their effects primarily as releasing agents.<ref>{{Cite journal|last1=Walker|first1=Q. David|last2=Morris|first2=Sarah E.|last3=Arrant|first3=Andrew E.|last4=Nagel|first4=Jacqueline M.|last5=Parylak|first5=Sarah|last6=Zhou|first6=Guiying|last7=Caster|first7=Joseph M.|last8=Kuhn|first8=Cynthia M.|date=October 2010|title=Dopamine Uptake Inhibitors but Not Dopamine Releasers Induce Greater Increases in Motor Behavior and Extracellular Dopamine in Adolescent Rats Than in Adult Male Rats|journal=The Journal of Pharmacology and Experimental Therapeutics|volume=335|issue=1|pages=124–132|doi=10.1124/jpet.110.167320|issn=0022-3565|pmc=2957786|pmid=20605908}}</ref><ref name="OffermannsRosenthal2008">{{cite book | author1 = Stefan Offermanns | author2 = Walter Rosenthal | title = Encyclopedia of Molecular Pharmacology | url = https://books.google.com/books?id=fGe6NDIGQpsC&pg=PA1039 | access-date = 12 May 2012 | year = 2008 | publisher = Springer | isbn = 978-3-540-38916-3 | page = 1039}}</ref> Additionally, psychostimulants acting as MRIs that affect dopamine such as [[cocaine]] and [[methylphenidate]] are often [[drug abuse|abused]] as [[recreational drug]]s.<ref name="RuizStrain2011">{{cite book | author1 = Pedro Ruiz | author2 = Eric C. Strain | title = Lowinson and Ruiz's Substance Abuse: A Comprehensive Textbook | url = https://books.google.com/books?id=w4ZUJAdleTsC&pg=PA55 | access-date = 12 May 2012 | date = 15 April 2011 | publisher = Lippincott Williams & Wilkins | isbn = 978-1-60547-277-5 | page = 55}}</ref> As a result, many of them have become [[controlled substance]]s, which in turn has resulted in the [[Clandestine chemistry|clandestine synthesis]] of a vast array of [[designer drug]]s for the purpose of bypassing [[drug prohibition law|drug law]]s; a prime example of such is the mixed monoamine reuptake inhibitor and [[monoamine releasing agent|releasing agent]] [[mephedrone]].<ref name="pmid21810934">{{cite journal |vauthors=Hadlock GC, Webb KM, McFadden LM, etal | title = 4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse | journal = The Journal of Pharmacology and Experimental Therapeutics | volume = 339 | issue = 2 | pages = 530–6 |date=November 2011 | pmid = 21810934 | doi = 10.1124/jpet.111.184119 | pmc = 3200001}}</ref> |
||
==Types of MRIs== |
==Types of MRIs== |
||
Line 23: | Line 24: | ||
{| class="wikitable sortable" style="text-align:left; font-size:small;" |
{| class="wikitable sortable" style="text-align:left; font-size:small;" |
||
|+ Binding profiles of {{abbr|MRIs|monoamine reuptake inhibitors}} at human {{abbr|MATs|monoamine transporters}}<ref name="pmid9537821">{{cite journal | vauthors = Tatsumi M, Groshan K, Blakely RD, Richelson E | title = Pharmacological profile of antidepressants and related compounds at human monoamine transporters | journal = Eur. J. Pharmacol. | volume = 340 | issue = 2–3 | pages = 249–58 | year = 1997 | pmid = 9537821 | doi = 10.1016/s0014-2999(97)01393-9| url = https://www.academia.edu/download/45762636/s0014-2999_2897_2901393-920160518-31441-t07hp6.pdf}}</ref> |
|+ Binding profiles of {{abbr|MRIs|monoamine reuptake inhibitors}} at human {{abbr|MATs|monoamine transporters}}<ref name="pmid9537821">{{cite journal | vauthors = Tatsumi M, Groshan K, Blakely RD, Richelson E | title = Pharmacological profile of antidepressants and related compounds at human monoamine transporters | journal = Eur. J. Pharmacol. | volume = 340 | issue = 2–3 | pages = 249–58 | year = 1997 | pmid = 9537821 | doi = 10.1016/s0014-2999(97)01393-9| url = https://www.academia.edu/download/45762636/s0014-2999_2897_2901393-920160518-31441-t07hp6.pdf}}{{dead link|date=July 2022|bot=medic}}{{cbignore|bot=medic}}</ref> |
||
|- |
|- |
||
! Compound !! {{abbrlink|SERT|Serotonin transporter}} !! {{abbrlink|NET|Norepinephrine transporter}} !! {{abbrlink|DAT|Dopamine transporter}} !! Type !! Class |
! Compound !! {{abbrlink|SERT|Serotonin transporter}} !! {{abbrlink|NET|Norepinephrine transporter}} !! {{abbrlink|DAT|Dopamine transporter}} !! Type !! Class |
||
Line 29: | Line 30: | ||
| [[Amfonelic acid]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || 207 || DRI || Stimulant |
| [[Amfonelic acid]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || 207 || DRI || Stimulant |
||
|- |
|- |
||
| [[Amineptine]]*<ref name="pmid3708219">{{cite journal | vauthors = Ceci A, Garattini S, Gobbi M, Mennini T | title = Effect of long term amineptine treatment on pre- and postsynaptic mechanisms in rat brain | journal = Br. J. Pharmacol. | volume = 88 | issue = 1 | pages = 269–75 | year = 1986 | pmid = 3708219 | pmc = 1917102 | doi = 10.1111/j.1476-5381.1986.tb09495.x}}</ref><ref name="pmid2698268">{{cite journal |vauthors=Garattini S, Mennini T |title=Pharmacology of amineptine: synthesis and updating |journal=Clin Neuropharmacol |volume=12 Suppl 2 |pages=S13–8 |year=1989 |pmid=2698268 |doi= 10.1097/00002826-198912002-00003}}</ref> || >100,000 (rat) || 10,000 (rat) || 1,000–1,400 (rat) || DRI || Stimulant |
| [[Amineptine]]*<ref name="pmid3708219">{{cite journal | vauthors = Ceci A, Garattini S, Gobbi M, Mennini T | title = Effect of long term amineptine treatment on pre- and postsynaptic mechanisms in rat brain | journal = Br. J. Pharmacol. | volume = 88 | issue = 1 | pages = 269–75 | year = 1986 | pmid = 3708219 | pmc = 1917102 | doi = 10.1111/j.1476-5381.1986.tb09495.x}}</ref><ref name="pmid2698268">{{cite journal |vauthors=Garattini S, Mennini T |title=Pharmacology of amineptine: synthesis and updating |journal=Clin Neuropharmacol |volume=12 Suppl 2 |pages=S13–8 |year=1989 |pmid=2698268 |doi= 10.1097/00002826-198912002-00003|s2cid=10947713 }}</ref> || >100,000 (rat) || 10,000 (rat) || 1,000–1,400 (rat) || DRI || Stimulant |
||
|- |
|- |
||
| [[Amitriptyline]] || 4.30 || 35 || 3,250 || SNRI || TCA |
| [[Amitriptyline]] || 4.30 || 35 || 3,250 || SNRI || TCA |
||
Line 59: | Line 60: | ||
| [[Cocaine]]<ref name="pmid14612135" /> || 304 || 779 || 478 || SNDRI || Stimulant |
| [[Cocaine]]<ref name="pmid14612135" /> || 304 || 779 || 478 || SNDRI || Stimulant |
||
|- |
|- |
||
| [[Cocaine]] |
| [[Cocaine]]<ref>http://www.emcdda.europa.eu/system/files/publications/1814/TDAS15001ENN.pdf {{Bare URL PDF|date=March 2022}}</ref> || 313±17 (IC<sub>50</sub>) || 292±34 (IC<sub>50</sub>) || 211±19 (IC<sub>50</sub>) || SNDRI || Stimulant |
||
|- |
|- |
||
| [[Desipramine]] || 17.6 || 0.83 || 3,190 || SNRI || TCA |
| [[Desipramine]] || 17.6 || 0.83 || 3,190 || SNRI || TCA |
||
Line 67: | Line 68: | ||
| [[Desmethylsertraline]] || 3.0 || 390 || 129 || SRI || SSRI |
| [[Desmethylsertraline]] || 3.0 || 390 || 129 || SRI || SSRI |
||
|- |
|- |
||
| [[Desmethylsibutramine]]<ref name="pmid12119986">{{cite journal | vauthors = Nisoli E, Carruba MO | title = An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action | journal = Obes Rev | volume = 1 | issue = 2 | pages = 127–39 | year = 2000 | pmid = 12119986 | doi = 10.1046/j.1467-789x.2000.00020.x}}</ref> || 15 || 20 || 49 || SNDRI || SNRI |
| [[Desmethylsibutramine]]<ref name="pmid12119986">{{cite journal | vauthors = Nisoli E, Carruba MO | title = An assessment of the safety and efficacy of sibutramine, an anti-obesity drug with a novel mechanism of action | journal = Obes Rev | volume = 1 | issue = 2 | pages = 127–39 | year = 2000 | pmid = 12119986 | doi = 10.1046/j.1467-789x.2000.00020.x| s2cid = 20553857 }}</ref> || 15 || 20 || 49 || SNDRI || SNRI |
||
|- |
|- |
||
| [[Desmethylsibutramine|(''R'')-Desmethylsibutramine]] || 44 || 4 || 12 || SNDRI || SNRI |
| [[Desmethylsibutramine|(''R'')-Desmethylsibutramine]] || 44 || 4 || 12 || SNDRI || SNRI |
||
Line 73: | Line 74: | ||
| [[Desmethylsibutramine|(''S'')-Desmethylsibutramine]] || 9,200 || 870 || 180 || SNDRI || SNRI |
| [[Desmethylsibutramine|(''S'')-Desmethylsibutramine]] || 9,200 || 870 || 180 || SNDRI || SNRI |
||
|- |
|- |
||
| [[Desoxypipradrol]]<ref name="pmid23261499">{{cite journal | vauthors = Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL | title = Neurochemical profiles of some novel psychoactive substances | journal = Eur. J. Pharmacol. | volume = 700 | issue = 1–3 | pages = 147–51 | year = 2013 | pmid = 23261499 | pmc = 3582025 | doi = 10.1016/j.ejphar.2012.12.006 }}</ref> || 53,700 || 550 || 50 || NDRI || Stimulant |
| [[Desoxypipradrol]]<ref name="pmid23261499">{{cite journal|author6-link=Bryan Roth | vauthors = Iversen L, Gibbons S, Treble R, Setola V, Huang XP, Roth BL | title = Neurochemical profiles of some novel psychoactive substances | journal = Eur. J. Pharmacol. | volume = 700 | issue = 1–3 | pages = 147–51 | year = 2013 | pmid = 23261499 | pmc = 3582025 | doi = 10.1016/j.ejphar.2012.12.006 }}</ref> || 53,700 || 550 || 50 || NDRI || Stimulant |
||
|- |
|- |
||
| [[Desvenlafaxine]]*<ref name="pmid16675639">{{cite journal | vauthors = Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH | title = Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor | journal = J. Pharmacol. Exp. Ther. | volume = 318 | issue = 2 | pages = 657–65 | year = 2006 | pmid = 16675639 | doi = 10.1124/jpet.106.103382 }}</ref> || 47 || 531 || {{abbr|ND|No data}} || SNRI || SNRI |
| [[Desvenlafaxine]]*<ref name="pmid16675639">{{cite journal | vauthors = Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH | title = Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor | journal = J. Pharmacol. Exp. Ther. | volume = 318 | issue = 2 | pages = 657–65 | year = 2006 | pmid = 16675639 | doi = 10.1124/jpet.106.103382 | s2cid = 15063064 }}</ref> || 47 || 531 || {{abbr|ND|No data}} || SNRI || SNRI |
||
|- |
|- |
||
| [[Didesmethylsibutramine]]<ref name="pmid12119986" /> || 20 || 15 || 45 || SNDRI || SNRI |
| [[Didesmethylsibutramine]]<ref name="pmid12119986" /> || 20 || 15 || 45 || SNDRI || SNRI |
||
Line 89: | Line 90: | ||
| [[Doxepin]] || 68 || 29.5 || 12,100 || SNRI || TCA |
| [[Doxepin]] || 68 || 29.5 || 12,100 || SNRI || TCA |
||
|- |
|- |
||
| [[Duloxetine]]*<ref name="pmid14744476">{{cite journal | vauthors = Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ | title = Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity | journal = Biol. Psychiatry | volume = 55 | issue = 3 | pages = 320–2 | year = 2004 | pmid = 14744476 | doi = 10.1016/j.biopsych.2003.07.006 }}</ref> || 3.7 || 20 || 439 || SNRI || SNRI |
| [[Duloxetine]]*<ref name="pmid14744476">{{cite journal | vauthors = Vaishnavi SN, Nemeroff CB, Plott SJ, Rao SG, Kranzler J, Owens MJ | title = Milnacipran: a comparative analysis of human monoamine uptake and transporter binding affinity | journal = Biol. Psychiatry | volume = 55 | issue = 3 | pages = 320–2 | year = 2004 | pmid = 14744476 | doi = 10.1016/j.biopsych.2003.07.006 | s2cid = 29448095 }}</ref> || 3.7 || 20 || 439 || SNRI || SNRI |
||
|- |
|- |
||
| [[Etoperidone]] || 890 || 20,000 || 52,000 || SRI || {{abbr|SARI|Serotonin antagonist and reuptake inhibitor}} |
| [[Etoperidone]] || 890 || 20,000 || 52,000 || SRI || {{abbr|SARI|Serotonin antagonist and reuptake inhibitor}} |
||
Line 101: | Line 102: | ||
| [[GBR-12935]]<ref name="pmid14612135" /> || 289 || 277 || 4.90 || DRI || Stimulant |
| [[GBR-12935]]<ref name="pmid14612135" /> || 289 || 277 || 4.90 || DRI || Stimulant |
||
|- |
|- |
||
| [[Hydroxybupropion]]<ref>{{cite journal |last1=Damaj |first1=MI |last2=Carroll |first2=FI |last3=Eaton |first3=JB |last4=Navarro |first4=HA |last5=Blough |first5=BE |last6=Mirza |first6=S |last7=Lukas |first7=RJ |last8=Martin |first8=BR |title=Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. |journal=Molecular Pharmacology |date=September 2004 |volume=66 |issue=3 |pages=675–82 |doi=10.1124/mol.104.001313 |pmid=15322260 }}</ref> || {{abbr|ND|No data}} || 1.7 (IC<sub>50</sub>) || >10 (IC<sub>50</sub>) || NDRI || Stimulant |
| [[Hydroxybupropion]]<ref>{{cite journal |last1=Damaj |first1=MI |last2=Carroll |first2=FI |last3=Eaton |first3=JB |last4=Navarro |first4=HA |last5=Blough |first5=BE |last6=Mirza |first6=S |last7=Lukas |first7=RJ |last8=Martin |first8=BR |title=Enantioselective effects of hydroxy metabolites of bupropion on behavior and on function of monoamine transporters and nicotinic receptors. |journal=Molecular Pharmacology |date=September 2004 |volume=66 |issue=3 |pages=675–82 |doi=10.1124/mol.104.001313 |pmid=15322260 |s2cid=1577336 }}</ref> || {{abbr|ND|No data}} || 1.7 (IC<sub>50</sub>) || >10 (IC<sub>50</sub>) || NDRI || Stimulant |
||
|- |
|- |
||
| [[Imipramine]] || 1.40 || 37 || 8,500 || SNRI || TCA |
| [[Imipramine]] || 1.40 || 37 || 8,500 || SNRI || TCA |
||
Line 127: | Line 128: | ||
| [[Dexmethylphenidate|D-Methylphenidate]] || >10,000 || 206 || 161 || NDRI || Stimulant |
| [[Dexmethylphenidate|D-Methylphenidate]] || >10,000 || 206 || 161 || NDRI || Stimulant |
||
|- |
|- |
||
| [[L-Methylphenidate]] || >6,700 || >10,000 || 2,250 || NDRI || Stimulant |
| [[Methylphenidate#Pharmacodynamics|L-Methylphenidate]] || >6,700 || >10,000 || 2,250 || NDRI || Stimulant |
||
|- |
|- |
||
| [[Mianserin]] || 4,000 || 71 || 9,400 || NRI || TeCA |
| [[Mianserin]] || 4,000 || 71 || 9,400 || NRI || TeCA |
||
Line 141: | Line 142: | ||
| [[Nefazodone]] || 200 || 360 || 360 || SNDRI || SARI |
| [[Nefazodone]] || 200 || 360 || 360 || SNDRI || SARI |
||
|- |
|- |
||
| [[Nefopam]]<ref name="pmid22711801">{{cite journal | vauthors = Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK | title = Identifying mechanism-of-action targets for drugs and probes | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 109 | issue = 28 | pages = 11178–83 | year = 2012 | pmid = 22711801 | pmc = 3396511 | doi = 10.1073/pnas.1204524109 }}</ref> || 29 || 33 || 531 || SNDRI || Analgesic |
| [[Nefopam]]<ref name="pmid22711801">{{cite journal | vauthors = Gregori-Puigjané E, Setola V, Hert J, Crews BA, Irwin JJ, Lounkine E, Marnett L, Roth BL, Shoichet BK | title = Identifying mechanism-of-action targets for drugs and probes | journal = Proc. Natl. Acad. Sci. U.S.A. | volume = 109 | issue = 28 | pages = 11178–83 | year = 2012 | pmid = 22711801 | pmc = 3396511 | doi = 10.1073/pnas.1204524109 | bibcode = 2012PNAS..10911178G | doi-access = free }}</ref> || 29 || 33 || 531 || SNDRI || Analgesic |
||
|- |
|- |
||
| [[Nisoxetine]]<ref name="pmid14612135" /> || 427 || 2.3 || 1,235 || NRI || Stimulant |
| [[Nisoxetine]]<ref name="pmid14612135" /> || 427 || 2.3 || 1,235 || NRI || Stimulant |
||
Line 157: | Line 158: | ||
| [[Protriptyline]] || 19.6 || 1.41 || 2,100 || SNRI || TCA |
| [[Protriptyline]] || 19.6 || 1.41 || 2,100 || SNRI || TCA |
||
|- |
|- |
||
| [[Reboxetine]]<ref name="pmid12665410">{{cite journal | vauthors = Bymaster FP, McNamara RK, Tran PV | title = New approaches to developing antidepressants by enhancing monoaminergic neurotransmission | journal = Expert Opin Investig Drugs | volume = 12 | issue = 4 | pages = 531–43 | year = 2003 | pmid = 12665410 | doi = 10.1517/13543784.12.4.531 }}</ref> || 129 || 1.1 || >10,000 || NRI || Stimulant |
| [[Reboxetine]]<ref name="pmid12665410">{{cite journal | vauthors = Bymaster FP, McNamara RK, Tran PV | title = New approaches to developing antidepressants by enhancing monoaminergic neurotransmission | journal = Expert Opin Investig Drugs | volume = 12 | issue = 4 | pages = 531–43 | year = 2003 | pmid = 12665410 | doi = 10.1517/13543784.12.4.531 | s2cid = 20039451 }}</ref> || 129 || 1.1 || >10,000 || NRI || Stimulant |
||
|- |
|- |
||
| [[Sertraline]] || 0.29 || 420 || 25 || SRI || SSRI |
| [[Sertraline]] || 0.29 || 420 || 25 || SRI || SSRI |
||
Line 171: | Line 172: | ||
| [[Venlafaxine]]*<ref name="pmid14744476" /> || 145 || 1,420 || 3,070 || SNRI || SNRI |
| [[Venlafaxine]]*<ref name="pmid14744476" /> || 145 || 1,420 || 3,070 || SNRI || SNRI |
||
|- |
|- |
||
| [[Vilazodone]]*<ref name="pmid12183683">{{cite journal | vauthors = Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I | title = Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist | journal = J. Pharmacol. Exp. Ther. | volume = 302 | issue = 3 | pages = 1220–7 | year = 2002 | pmid = 12183683 | doi = 10.1124/jpet.102.034280 }}</ref> || 0.2 || ~60 || {{abbr|ND|No data}} || SRI || {{abbr|SMS|Serotonin modulator and stimulator}} |
| [[Vilazodone]]*<ref name="pmid12183683">{{cite journal | vauthors = Page ME, Cryan JF, Sullivan A, Dalvi A, Saucy B, Manning DR, Lucki I | title = Behavioral and neurochemical effects of 5-(4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl)-benzofuran-2-carboxamide (EMD 68843): a combined selective inhibitor of serotonin reuptake and 5-hydroxytryptamine(1A) receptor partial agonist | journal = J. Pharmacol. Exp. Ther. | volume = 302 | issue = 3 | pages = 1220–7 | year = 2002 | pmid = 12183683 | doi = 10.1124/jpet.102.034280 | s2cid = 12020750 }}</ref> || 0.2 || ~60 || {{abbr|ND|No data}} || SRI || {{abbr|SMS|Serotonin modulator and stimulator}} |
||
|- |
|- |
||
| [[Viloxazine]] || 17,300 || 155 || >100,000 || NRI || Stimulant |
| [[Viloxazine]] || 17,300 || 155 || >100,000 || NRI || Stimulant |
||
Line 189: | Line 190: | ||
==External links== |
==External links== |
||
*{{ |
*{{Commons category-inline|Monoamine reuptake inhibitors}} |
||
{{Monoamine reuptake inhibitors}} |
{{Monoamine reuptake inhibitors}} |
Amonoamine reuptake inhibitor (MRI)[1] is a drug that acts as a reuptake inhibitor of one or more of the three major monoamine neurotransmitters serotonin, norepinephrine, and dopamine by blocking the action of one or more of the respective monoamine transporters (MATs), which include the serotonin transporter (SERT), norepinephrine transporter (NET), and dopamine transporter (DAT). This in turn results in an increase in the synaptic concentrations of one or more of these neurotransmitters and therefore an increase in monoaminergic neurotransmission.
The majority of currently approved antidepressants act predominantly or exclusively as MRIs, including the selective serotonin reuptake inhibitors (SSRIs), serotonin–norepinephrine reuptake inhibitors (SNRIs), and almost all of the tricyclic antidepressants (TCAs).[2] Many psychostimulants used either in the treatment of ADHDTooltip attention-deficit hyperactivity disorder or as appetite suppressants in the treatment of obesity also behave as MRIs, although notably amphetamine (and methamphetamine), which do act to some extent as monoamine reuptake inhibitors, exerts their effects primarily as releasing agents.[3][4] Additionally, psychostimulants acting as MRIs that affect dopamine such as cocaine and methylphenidate are often abusedasrecreational drugs.[5] As a result, many of them have become controlled substances, which in turn has resulted in the clandestine synthesis of a vast array of designer drugs for the purpose of bypassing drug laws; a prime example of such is the mixed monoamine reuptake inhibitor and releasing agent mephedrone.[6]
There are a variety of different kinds of MRIs, of which include the following:
Compound | SERTTooltip Serotonin transporter | NETTooltip Norepinephrine transporter | DATTooltip Dopamine transporter | Type | Class | |
---|---|---|---|---|---|---|
Amfonelic acid | ND | ND | 207 | DRI | Stimulant | |
Amineptine*[8][9] | >100,000 (rat) | 10,000 (rat) | 1,000–1,400 (rat) | DRI | Stimulant | |
Amitriptyline | 4.30 | 35 | 3,250 | SNRI | TCA | |
Amoxapine | 58 | 16.0 | 4,310 | SNRI | TeCA | |
Amphetamine | >100,000 | ND | ND | NDRA | Stimulant | |
D-Amphetamine | >100,000 | 530 | 2,900 | NDRA | Stimulant | |
L-Amphetamine | >100,000 | ND | ND | NRA | Stimulant | |
Atomoxetine | 77 | 5 | 1,451 | NRI | Stimulant | |
Bupropion | 9,100 | 52,000 | 520 | NDRI | Stimulant | |
Butriptyline | 1,360 | 5,100 | 3,940 | N/A (IA) | TCA | |
Chlorphenamine | 15.2 | 1,440 | 1,060 | SRI | Antihistamine | |
Citalopram | 1.16 | 4,070 | 28,100 | SRI | SSRI | |
Escitalopram[10] | 1.1 | 7,841 | 27,410 | SRI | SSRI | |
Clomipramine | 0.28 | 38 | 2,190 | SNRI | TCA | |
Cocaethylene[11] | 3,878 | >10,000 | 555 | SDRI | Stimulant | |
Cocaine[11] | 304 | 779 | 478 | SNDRI | Stimulant | |
Cocaine[12] | 313±17 (IC50) | 292±34 (IC50) | 211±19 (IC50) | SNDRI | Stimulant | |
Desipramine | 17.6 | 0.83 | 3,190 | SNRI | TCA | |
Desmethylcitalopram | 3.6 | 1,820 | 18,300 | SRI | SSRI | |
Desmethylsertraline | 3.0 | 390 | 129 | SRI | SSRI | |
Desmethylsibutramine[13] | 15 | 20 | 49 | SNDRI | SNRI | |
(R)-Desmethylsibutramine | 44 | 4 | 12 | SNDRI | SNRI | |
(S)-Desmethylsibutramine | 9,200 | 870 | 180 | SNDRI | SNRI | |
Desoxypipradrol[14] | 53,700 | 550 | 50 | NDRI | Stimulant | |
Desvenlafaxine*[15] | 47 | 531 | ND | SNRI | SNRI | |
Didesmethylsibutramine[13] | 20 | 15 | 45 | SNDRI | SNRI | |
(R)-Didesmethylsibutramine | 140 | 13 | 8.9 | SNDRI | SNRI | |
(S)-Didesmethylsibutramine | 4,300 | 62 | 12 | SNDRI | SNRI | |
Diphenhydramine | 3,800 | 960 | 2,200 | N/A (IA) | Antihistamine | |
Dosulepin (dothiepin) | 8.6 | 46 | 5,310 | SNRI | TCA | |
Doxepin | 68 | 29.5 | 12,100 | SNRI | TCA | |
Duloxetine*[16] | 3.7 | 20 | 439 | SNRI | SNRI | |
Etoperidone | 890 | 20,000 | 52,000 | SRI | SARI | |
Femoxetine | 11.0 | 760 | 2,050 | SRI | SSRI | |
Fluoxetine | 0.81 | 240 | 3,600 | SRI | SSRI | |
Fluvoxamine | 2.2 | 1,300 | 9,200 | SRI | SSRI | |
GBR-12935[11] | 289 | 277 | 4.90 | DRI | Stimulant | |
Hydroxybupropion[17] | ND | 1.7 (IC50) | >10 (IC50) | NDRI | Stimulant | |
Imipramine | 1.40 | 37 | 8,500 | SNRI | TCA | |
Indatraline[11] | 3.10 | 12.6 | 1.90 | SNDRI | Stimulant | |
Iprindole | 1,620 | 1,262 | 6,530 | N/A (IA) | TCA | |
Lofepramine | 70 | 5.4 | 18,000 | SNRI | TCA | |
Maprotiline | 5,800 | 11.1 | 1,000 | NRI | TeCA | |
Mazindol | 39 | 0.45 | 8.1 | NDRI | Stimulant | |
MDPVTooltip Methylenedioxypyrovalerone[18] | 3,349 | 26 | 4.1 | NDRI | Stimulant | |
Methamphetamine | >100,000 | ND | ND | NDRA | Stimulant | |
D-Methamphetamine | >100,000 | 660 | 2,800 | NDRA | Stimulant | |
L-Methamphetamine | >100,000 | ND | ND | NRA | Stimulant | |
Methylphenidate | >10,000 | 788 | 121 | NDRI | Stimulant | |
D-Methylphenidate | >10,000 | 206 | 161 | NDRI | Stimulant | |
L-Methylphenidate | >6,700 | >10,000 | 2,250 | NDRI | Stimulant | |
Mianserin | 4,000 | 71 | 9,400 | NRI | TeCA | |
Milnacipran*[16] | 151 | 68 | >100,000 | SNRI | SNRI | |
Levomilnacipran*[19] | 19.0 | 10.5 | >100,000 | SNRI | SNRI | |
Mirtazapine | >100,000 | 4,600 | >100,000 | N/A (IA) | TeCA | |
Modafinil*[20] | >50,000 | 136,000 | 4,043 | DRI | Stimulant | |
Nefazodone | 200 | 360 | 360 | SNDRI | SARI | |
Nefopam[21] | 29 | 33 | 531 | SNDRI | Analgesic | |
Nisoxetine[11] | 427 | 2.3 | 1,235 | NRI | Stimulant | |
Nomifensine | 1,010 | 15.6 | 56 | NDRI | Stimulant | |
Norfluoxetine | 1.47 | 1,426 | 420 | SRI | SSRI | |
Nortriptyline | 18 | 4.37 | 1,140 | SNRI | TCA | |
Oxaprotiline | 3,900 | 4.9 | 4,340 | NRI | TeCA | |
Paroxetine | 0.13 | 40 | 490 | SRI | SSRI | |
Protriptyline | 19.6 | 1.41 | 2,100 | SNRI | TCA | |
Reboxetine[22] | 129 | 1.1 | >10,000 | NRI | Stimulant | |
Sertraline | 0.29 | 420 | 25 | SRI | SSRI | |
Sibutramine[13] | 298–2,800 | 350–5,451 | 943–1,200 | SNDRI | SNRI | |
Trazodone | 160 | 8,500 | 7,400 | SRI | SARI | |
Trimipramine | 149 | 2,450 | 3,780 | SRI | TCA | |
Vanoxerine[11] | 73.2 | 79.2 | 4.3 | DRI | Stimulant | |
Venlafaxine*[16] | 145 | 1,420 | 3,070 | SNRI | SNRI | |
Vilazodone*[23] | 0.2 | ~60 | ND | SRI | SMS | |
Viloxazine | 17,300 | 155 | >100,000 | NRI | Stimulant | |
Vortioxetine*[24] | 5.4 | 890 (rat) | 140 (rat) | SRI | SMS | |
Zimelidine | 152 | 9,400 | 11,700 | SRI | SSRI | |
Values are Ki (nM) or, in some cases (*), IC50Tooltip half-maximal inhibitory concentration (nM). The smaller the value, the more strongly the drug binds to or inhibits the transporter. |